No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ANIX Anixa Biosciences
- 2.980
- -0.200-6.29%
Close Apr 25 16:00 ET
- 2.970
- -0.010-0.34%
Post 19:55 ET
95.06MMarket Cap-8764P/E (TTM)
3.320High2.940Low251.93KVolume3.250Open3.180Pre Close786.13KTurnover0.83%Turnover RatioLossP/E (Static)31.90MShares5.13052wk High3.87P/B90.54MFloat Cap2.75052wk Low--Dividend TTM30.38MShs Float8.950Historical High--Div YieldTTM11.95%Amplitude0.056Historical Low3.120Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Anixa Biosciences Welcomes Celebrity Oncologist DR. Sanjay Juneja to Its Cancer Business Advisory Board
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to Its Cancer Business Advisory Board
Anixa Chairman and CEO Dr. Amit Kumar stated, "Dr. Juneja is an accomplished medical oncologist who has earned status as a top media personality on cancer prevention and treatment innovations.
Anixa Biosciences(ANIX.US) Director Buys US$49,229.52 in Common Stock
$Anixa Biosciences(ANIX.US)$ Director Titterton Lewis H jr purchased 15,009 shares of common stock on Apr 9, 2024 at an average price of $3.28 for a total value of $49,229.52.Source: Announcement What
Anixa Biosciences Stockholders Affirm Confidence and Oversight
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
Anixa Biosciences: A Buy Rating on Strong Financials and Promising Oncology Advances
Comments
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Fish4 : BUY